Europe IT Spending on Business Intelligence to 2012 Pharmaceutical Technology

Summary

Introduction

Although BI in the earlier stages of drug development remains an emergent solution area in the pharmaceutical market, contextual forces such as pipeline productivity pressures and growing generic competition will drive increased spending on BI in the near future.

Scope

• Identifies potential growth areas for technology in Big Pharma in Europe
• Quantifies spending on BI solutions by pharmaceutical end-user segments
• Segments IT spending by technology, country and end-user group

Highlights

The adoption of BI solutions will exhibit strong growth over the next five years.

The Biotech segment will increase their spending on BI solutions more quickly than Big Pharma

BI adoption by clinical end-user groups will demonstrate the most rapid growth compared to R&D, manufacturing and sales & marketing groups.

Reasons to Purchase

• Understand the potential opportunity size for BI solutions in the pharmaceutical market.
• Identify the BI technology areas in which pharmaceutical companies will invest the most heavily.
• Recognize the differences in BI spending across segments of the market and end-user groups.

Contents

• Overview
• Catalyst
• Summary
• Methodology
• Introduction
  • Spending by the US and Europe pharmaceutical industry on BI to 2012
  • Spending by the Big Pharma in Europe on BI to 2012
  • Spending on BI solutions by US pharmaceutical sub-segments to 2012
  • Spending by US Big Pharma on BI solutions by technology to 2012
  • Spending by Global Big Pharma on BI solutions by end-user group to 2012
  • Spending by Global Biotech on BI solutions by end-user group to 2012
• Appendix
  • Definitions
  • Further reading
  • Ask the analyst
  • Datamonitor consulting
  • Table 1: Spending by US and Europe pharmaceutical industry on BI solutions to 2012
  • Table 2: Spending by the Big Pharma in Europe on BI to 2012
  • Table 3: Spending on BI solutions by Big Pharma in the UK, France, Switzerland and Germany to 2012
  • Table 4: Spending by Big Pharma in Europe on BI solutions by technology
  • Table 5: Spending by Big Pharma on BI solutions by end-user group to 2012 (US & Europe)
  • Table 6: Spending by Biotech on BI solutions by end-user group to 2012 (US)
  • Figure 1: Spending by US and Europe pharmaceutical industry on BI solutions to 2012
  • Figure 2: Spending by the Big Pharma in Europe on BI to 2012
  • Figure 3: Spending on BI solutions by Big Pharma in the UK, France, Switzerland and Germany to 2012
  • Figure 4: Spending by Big Pharma in Europe on BI solutions by technology
  • Figure 5: Spending by Big Pharma on BI solutions by end-user group to 2012 (US & Europe)
  • Figure 6: Spending by Biotech on BI solutions by end-user group to 2012 (US)

Related products